AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio
BioSpace
While AstraZeneca has discontinued work on four assets--including one in asthma and another in acromegaly--the pharma has also elected to take forward a bispecific antibody that destroys the EGFR protei
pharminent
April 30, 2026 (Last updated: April 30, 2026)
BioSpace
While AstraZeneca has discontinued work on four assets–including one in asthma and another in acromegaly–the pharma has also elected to take forward a bispecific antibody that destroys the EGFR protei
